Meeting
2023 ASCO Breakthrough
The preventive effects of early short-course corticosteroids on immune-related adverse events in non-small cell lung cancer patients receiving immune checkpoint inhibitors.
Authors
Derek Huang
National Taiwan University Cancer Center, Taipei, Taiwan
Derek Huang , Bin-Chi Liao , Ann-Lii Cheng , James Chih-Hsin Yang , Ying-Chun Shen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics
Sub Track
Immunotherapies
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 144)
DOI
10.1200/GO.2023.9.Supplement_1.144
Abstract #
144
Poster Bd #
H6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Comparing the impact of steroid sparing immunosuppression vs. steroid monotherapy for immune-related adverse events in non–small cell lung cancer and melanoma.
First Author: Sharjeel Syed
Poster
2020 ASCO Virtual Scientific Program
Real-world outcomes of immune-related adverse events in 2,125 patients managed with immunotherapy: A United Kingdom multicenter series.
First Author: Anna Claire Olsson-Brown
Poster
2024 ASCO Genitourinary Cancers Symposium
Breaking boundaries: Exploring extended pembrolizumab in first-line treatment of renal cell carcinoma with axitinib-pembrolizumab combination.
First Author: Can Aydogdu
Poster
2023 ASCO Annual Meeting
FDA analysis of toxicity profiles of oral TKIs recently approved for non-small cell lung cancer based on receipt of prior immune checkpoint inhibitor therapy.
First Author: Yufan Liu